The Effect of Major Surgical Procedures on Plasma and Platelet Levels of Factor XIII

Summary

Factor XIII (FSF or fibrinoligase), an enzyme required for normal blood coagulation, can be measured by its catalysis of the incorporation of a fluorescent amine, monodansylcadaverine (N-(5-aminopentyl)-5-dimethylamino-l-naphthalene-sulfon-amide) into casein. The amine incorporation test was applied to fourteen patients who had major operations. Levels of factor XIII were measured before surgery and at intervals of two, four, and six days after operation. Plasma factor XIII showed a significant, linear decrease for each day after surgery. Patients having orthopedic surgery showed less pronounced changes than the remaining patients. Factor XIII also decreased after operation in patients with neoplastic disease, but the change was not different from that after general surgical procedures done in the absence of neoplasia. Platelet factor XIII levels were increased on the second day after operation, diminished on day four, and increased above pre-operative levels on the sixth day after surgery. Possible explanations of the observations are presented.

• References

• 1 Alami S. Y, Hampton J. W, Race G. J, Speer R. J. Fibrin stabilizing factor (Factor XIII). American Journal of Medicine 1968; 44: 1
• 2 AzIz M. A, Siddiqui A. R. Congenital deficiency of fibrin stabilizing factor (Factor XIII), Report of 4 cases (two families) and family members. Blood 1972; 40: 11
• 3 Beck E, Duckert F, Ernst M. The influence of fibrin stabilizing factor on the growth of fibroblasts in vitro and wound healing. Thrombosis et Diathesis Haemorrh-agica 1961; 6: 485
• 4 Bohn H. Immunochemical studies on the fibrin stabilizing factor from human plasma and platelets. Blut 1971; 22: 237
• 5 Britten A. F. H. Congenital deficiency of Factor XIII (Fibrin stabilizing factor). American Journal of Medicine 1967; 43: 751
• 6 Chung S. I, Folk J. E. Kinetic studies with transglutaminases. The human blood enzymes (activated coagulation Factor XIII) and the guinea pig hair follicle enzyme. Journal of Biological Chemistry 1972; 247: 2798
• 7 Coopland A, Alkjaersig A, Fletcher A. P. Reduction in plasma factor XIII (fibrin stabilizing factor) concentration during pregnancy. Journal of Laboratory and Clinical Medicine 1969; 73: 144
• 8 Duckert D, Jung E, Shmerling D. H. A hitherto undescribed congenital hemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thrombosis et Diathesis Haemorrhagica 1960; 5: 179
• 9 Dvilansky A, Britten A. F. H, Loewy A. G. Factor XIII assay by an isotope method I. Factor XIII (transamidase) in plasma, serum, leukocytes, erythrocytes, and platelets and evaluation of screening tests of clot solubility. British Journal of Haematology 1970; 18: 399
• 10 Gierhake F. W, Volkmann W, Becker W, Schwarz H, Schwick H. Factor XIII Konzentration und Wundheilung. Deutsche Medizinische Wochenschrift 1970; 95: 1472
• 11 Godal H.C. An inhibitor to fibrin stabilizing factor (FSF) factor XIII. Scandi-navian Journal of Hematology 1970; 7: 43
• 12 Hampton J. W, Bird R. M, Hammarsten D. M. Defective fibrinase activity in two brothers. Journal of Laboratory and Clinical Medicine 1965; 65: 469
• 13 Hosenfeld D, Dunnweber E, Kaiser X. Das Verhalten des Faktors XIII nach Operationen. 2. Mitteilung Med. Welt 1969; 20: 1170
• 14 Hosenfeld D, Kaiser N. Das Verhalten des Faktors XIII nach Operationen I. Mitteilung. Med. Welt 1969; 6: 286
• 15 Kiesselbach T. H, Wagner R. H. Fibrin stabilizing factor: A thrombin-labile platelet protein. American Journal of Physiology 1966; 211: 1472
• 16 Lewis M, Alkjaersig X, Fletcher A. Depression of plasma factor XIII (F S. F.) concentration during blood hypercoagulability and intravascular coagulation. Clinical Research 1972; 20: 789
• 17 Lorand L, Maldonado X, Fradera J, Atencio A.C, Robertson B, Ura-yama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (Factor XIII). British Journal of Haematology 1972; 23: 17
• 18 Lorand L, Urayama T, Dekiewiet J. W. C, Nossel H. L. Diagnostic and genetic studies on fibrin stabilizing factor with a new assay based on amine incorporation. Journal of Clinical Investigation 1969; 48: 1054
• 19 Mandel E. E, Gerhold W. M. Plasma fibrin stabilizing factor: Acquired deficiency in various disorders. American Journal of Clinical Pathology 1969; 52: 547
• 20 McDonagh J, Kiesselbach T. H, Wagner R. H. Factor XIII and antiplasmin activity in human platelets. American Journal of Physiology 1969; a 216: 508
• 21 McDonagh J, Kiesselbach T. H, Wagner R. H. Origin of platelet Factor XIII (fibrin stabilizing factors (abs). Federation Proceedings 1969; b 28: 745
• 22 McDonagh J, McDonagh Jr. R. P, Delage J. M, Wagner R. H. Factor XIII in human plasma and platelets. Journal of Clinical Investigation 1969; c 48: 940
• 23 McDonagh J, Wagner R. H. Separation of plasma and platelet Factor XIII by gel filtration. American Journal of Physiology 1970; 219: 1555
• 24 Merskey C, Johnson A. J, Kleiner G. J, Wohl H. The defibrination syndrome: Clinical features and laboratory diagnosis. British Journal of Haematology 1967; 13: 528
• 25 Miller I, Freund E. Probability and Statistics for Engineers. New Jersey: Prentice-Hall; 1965. Inc., pp. 226, 240 254
• 26 Rookstool D. J, Bannerjee D, Kalmaz E, Totoro J, Grimsley W.A, Bitsbee C. J, Hampton J. W. Site of Synthesis for plasma and platelet transglutaminase by immunofluorescent techniques. Clinical Research 1972; 20: 742
• 27 Schwartz M. L, Pizzo S. V, Hill R. L, McKee P. A. The subunit structures of human plasma and platelet factor XIII (fibrin stablizing factor). Journal of Biological Chemistry 1971; 246: 5851
• 28 Sturm G, Hellinger J. Factor XIII Bestimmung nach orthopädischen Operationen. Beitr 1970; Orthopedic Traumatol. 17: 485